Participated · Series B · Oct 2022

FEMSelect develops EnPlace®, a minimally invasive, meshless system for pelvic floor ligament fixation cleared by the FDA to manage symptomatic uterine prolapse. The technology enables a procedure in under 30 minutes, and clinical studies report women can return to normal activities within a few days. FEMSelect has partnered with LiNA Medical USA and has spent the past year educating physicians on the technology. The company obtained a CMS procedure code earlier this year, enabling healthcare facilities to receive reimbursement for the procedure. EnPlace is currently available in more than 25 US states. FEMSelect plans to use the Series B proceeds to support growth and market penetration of EnPlace, primarily in the US; the company is led by Co-CEOs Debbie Garner and Renee Selman. POP Medical Solutions Ltd. develops NeuGuide, a minimally-invasive, meshless and dissectionless surgical system to treat pelvic organ prolapse (POP). NeuGuide combines a Nitinol-based anchor, surgical sutures and an innovative attachment method and has received FDA clearance. The device was tested in a 15-patient trial in Israel and is currently being used by US physicians in a post-marketing study. POP plans to use new funding to complete the post-marketing study, obtain European CE Mark certification, transfer the product to mass production, and build a US commercial organization for an early 2019 launch. CEO Deborah Garner leads the company and MABA founder Bernie Rudnick will join POP's board as part of the financing.

Led · Series A · Aug 2022

iQure Pharma is a Princeton, NJ-based biotech focused on developing therapeutics for neuropathic pain, epilepsy, and wider neurodegenerative diseases. The company is advancing preclinical candidates iQ-007 and iQ-008. iQ-007 has demonstrated positive results in NIH ETSP tests suggesting activity against pain, epilepsy, and potentially neurodegenerative conditions. iQ-008, described as a novel analgesic compound, has progressed within the NIH PSPP program for pain and is moving to the next stage of that screening platform under the HEAL initiative. Led by Coo Pawel Zolnierczyk, iQure intends to use the funds raised to support research into neuropathic pain compounds. Financially, iQure completed an early closing of its Series A, raising $600K from Keiretsu Mid-Atlantic and associated business angels.

Participated · Series A · May 2019

Astarte Medical develops NICUtrition®, an EMR-integrated clinical decision support platform that standardizes feeding, optimizes nutrition, and assesses equitable care in neonatal intensive care units. The company applies software and predictive analytics to address malnutrition, suboptimal growth, and racial disparities in NICU care during the first 1,000 days. Astarte has signed contracts and has implementations underway at its initial NICU sites. The company announced a $7.6 million Series A-1 financing to support growth. Management says the funds will be used to scale sales of NICUtrition and expand customer adoption. Wendy Slatery joined the board to provide commercial and market-entry guidance. Astarte Medical is a precision medicine company based in Yardley, Pa., that uses software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants. Its first two solutions, NICUtrition Analytics and NICUtrition Guidance, support feeding protocols, decision-making and nutrition optimization in the neonatal ICU, and include digital tools and diagnostics to standardize feeding and quantify gut health. Led by CEO and co-founder Tracy Warren, the company plans to grow its team by 300% in 2020, adding in-house sales, marketing and client support to assist early adopters. It also intends to expand its engineering and data science teams to support continued product development. Astarte will use the new financing to accelerate hiring and ramp sales and marketing for its NICUtrition products, develop a regulatory strategy in support of a 2020 MAGI trial, and build a health disparities platform. The company additionally plans to explore and isolate novel therapeutic and diagnostic candidates. Astarte Medical develops NICUtrition®, a suite of digital tools and diagnostics that support feeding protocols, decision-making and practice in the neonatal ICU. The platform is designed to standardize feeding, optimize nutrition and quantify gut health for preterm infants. Core to Astarte’s product is a proprietary dataset that integrates feeding protocols, microbial profiles and clinical information to enable predictive analytics. The company focuses on improving outcomes during the first 1,000 days of life, with an initial emphasis on premature infants. Astarte recently graduated from the Illumina Accelerator and is led by CEO and co-founder Tracy Warren. The company is based in Yardley, Pa., and will use the Series A proceeds to complete development of the NICUtrition suite. Astarte Medical develops software to support care of preterm infants by providing quantitative data about gut health to enable personalized care and nutrition. Its first product, NICUtrition Guidance, is a rules engine designed to standardize enteral feeding for preterm infants. The company plans to develop MAGI, a gut-health score intended to improve growth and development of preemies while lowering medical treatment costs. Astarte was co-founded by Tracy Warren, Tammi Jantzen, and Katherine Gregory and is based in Yardley, PA. The company has received an investment from Next Act Fund and is currently raising money to launch and support NICUtrition Guidance. The amount of the investment disclosed in the article was not provided.

Led · Equity · Nov 2015

Tassl builds a software platform and mobile app designed to enhance utilization of alumni networks and communities by promoting information sharing, connectivity, and engagement. The company presented at Keiretsu Forum Mid-Atlantic’s Angel Capital Expo and was voted the event’s most favored company. As a result of the Expo, Keiretsu Forum members made a $100,000 investment in Tassl, and the company received a separate top-company award totaling $50,000 in investment and services. The $50,000 award included $25,000 of direct investment from Howard Lubert and Vince Leusner and $12,500 each in tax and intellectual-property legal services from Drucker & Scaccetti and BakerHostetler. The article does not disclose revenue, user counts, or the company’s founding year. Tassl’s public profile in the article is centered on its product and the capital and professional services secured at the Expo.